SCHEMBL15344951

SCHEMBL15344951

Cc1ccnc(-c2ccc3c(c2)OCC(=O)N3C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.59
CYP11B1 P15538 2/20 0.59
PDE3B Q13370 2/20 0.51
PDE3A Q14432 2/20 0.51
GABRA5 P31644 3/20 0.45
GABRG2 P18507 2/20 0.45
GABRB3 P28472 2/20 0.45
CYP2A6 P11509 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
GABRA1 P14867 1/20 0.39
TRIM24 O15164 1/20 0.38
BRD4 O60885 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
SLC6A4 P31645 1/20 0.38
KCNH2 Q12809 1/20 0.38
KDM1A O60341 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345168 0.90 PDE3B (0.54) CYP11B2CYP11B1PDE3BPDE3AGABRA5
SCHEMBL15341890 0.85 CYP11B2 (0.55) CYP11B2CYP11B1PDE3BPDE3AGABRA5
SCHEMBL5985192 0.80 CYP11B2 (0.55) CYP11B2CYP11B1PDE3BPDE3AGABRA5
SCHEMBL15344925 0.77 TRIM24 (0.62) CYP11B2CYP11B1CYP2A6CCR1CCR5
SCHEMBL15345147 0.76 CYP11B1 (0.57) CYP11B2CYP11B1CYP2A6CCR1CCR5
SCHEMBL15341905 0.76 GPR55 (0.51) CYP11B2CYP11B1PDE3BPDE3AGABRA5
SCHEMBL1119473 0.74 CYP11B1 (1.00) CYP11B2CYP11B1PDE3BPDE3AGABRA5
SCHEMBL15344952 0.74 CYP11B1 (0.55) CYP11B2CYP11B1PDE3BPDE3A
SCHEMBL15345022 0.73 PDE3B (0.44) CYP11B2CYP11B1PDE3BPDE3ACYP2A6
SCHEMBL16474930 0.72 CYP11B2 (0.51) CYP11B2CYP11B1PDE3BPDE3AGABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP11B2 19/4885CYP11B1 20/4885PDE3B 763/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP11B2 19/4885CYP11B1 20/4885PDE3B 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.